Skip to main content

Transapical Mitral Valve Replacement: 1-Year Results of the Real-World Tendyne European Experience Registry.

JACC. Cardiovascular interventions

Authors: Michaela M Hell, Mirjam G Wild, Stephan Baldus, Tanja Rudolph, Hendrik Treede, Anna Sonia Petronio, Thomas Modine, Martin Andreas, Augustin Coisne, Alison Duncan, Luis Nombela Franco, Fabien Praz, Hendrik Ruge, Lenard Conradi, Andreas Zierer, Amedeo Anselmi, Nicolas Dumonteil, Georg Nickenig, Miguel Piñón, Sebastian Barth, Marianna Adamo, Christophe Dubois, Lucia Torracca, Francesco Maisano, Philipp Lurz, Ralph Stephan von Bardeleben, Jörg Hausleiter

BACKGROUND: Early studies of the Tendyne transcatheter mitral valve replacement (TMVR) showed promising results in a small selective cohort.

OBJECTIVES: The authors present 1-year data from the currently largest commercial, real-world cohort originating from the investigator-initiated TENDER (Tendyne European Experience) registry.

METHODS: All patients from the TENDER registry eligible for 1-year follow-up were included. The primary safety endpoint was 1-year cardiovascular mortality. Primary performance endpoint was reduction of mitral regurgitation (MR) up to 1 year.

RESULTS: Among 195 eligible patients undergoing TMVR (median age 77 years [Q1-Q3: 71-81 years], 60% men, median Society of Thoracic Surgeons Predicted Risk of Mortality 5.6% [Q1-Q3: 3.6%-8.9%], 81% in NYHA functional class III or IV, 94% with MR 3+/4+), 31% had "real-world" indications for TMVR (severe mitral annular calcification, prior mitral valve treatment, or others) outside of the instructions for use. The technical success rate was 95%. The cardiovascular mortality rate was 7% at 30 day and 17% at 1 year (all-cause mortality rates were 9% and 29%, respectively). Reintervention or surgery following discharge was 4%, while rates of heart failure hospitalization reduced from 68% in the preceding year to 25% during 1-year follow-up. Durable MR reduction to ≤1+ was achieved in 98% of patients, and at 1 year, 83% were in NYHA functional class I or II. There was no difference in survival and major adverse events between on-label use and "real-world" indications up to 1 year.

CONCLUSIONS: This large, real-world, observational registry reports high technical success, durable and complete MR elimination, significant clinical benefits, and a 1-year cardiovascular mortality rate of 17% after Tendyne TMVR. Outcomes were comparable between on-label use and "real-world" indications, offering a safe and efficacious treatment option for patients without alternative treatments. (Tendyne European Experience Registry [TENDER]; NCT04898335).

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

PMID: 38385922

Participating cluster members